文献速递眼底病与葡萄膜炎白内障与屈光手术

ABCA4相关Stargardt病患者晶状体混浊的ProgStar研究

Lens Opacity in ABCA4-Associated Stargardt Disease Patients in the ProgStar Study.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

该研究基于多中心ProgStar研究二次分析,纳入259例分子确诊的STGD1患者(≥6岁),用AREDS方案评估晶状体混浊(LO)。基线LO患病率14.3%(69/483眼),2年发生率5.6%;年龄增长和发病年龄较晚与LO患病相关,年龄增长也与LO发生相关。核性白内障最常见。

要点

  • STGD1患者基线LO患病率14.3%,高于年龄匹配普通人群。

核心结论

  • ProgStar研究中STGD1患者LO患病率高于年龄匹配的普通人群。
  • 年龄和发病年龄是LO的危险因素,提示STGD1视网膜变性可能伴随生物性及加速老化。
  • STGD1试验应密切监测前节安全性,并考虑排除近期拟行白内障手术的患者。

研究设计与样本

  • 多中心ProgStar研究的二次分析,纳入美国与欧洲分子确诊的STGD1患者,年龄≥6岁,随访2年。
  • 共259例参与者,基线中位年龄31岁(IQR 21-44,范围6-68),女性54%,白人86%,发病中位年龄19岁。
  • 采用AREDS方案在裂隙灯检查中分级LO,估计基线患病率和2年发生率。
  • 使用广义估计方程的逻辑回归识别LO相关危险因素。

主要发现

  • 基线LO患病率为14.3%(69/483研究眼)。
  • 基线无LO的354眼中,2年LO发生率为5.6%。

关键数值与推荐

  • LO分级采用AREDS方案。
  • 基线LO患病率14.3%(69/483眼),2年发生率5.6%(354眼)。

临床怎么用

  • 对STGD1患者进行前节评估时,应关注年龄较大和发病较晚者的晶状体混浊。
  • 在STGD1临床试验中,应密切监测前节安全性。
  • 试验设计可考虑排除近期拟行白内障手术的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to estimate lens opacity (LO) and associated risk factors in patients with ABCA4 associated Stargardt disease (STGD1). METHODS: This is a secondary analysis of the multicenter ProgStar study. Patients with molecularly confirmed STGD1 aged ≥6 years from the United States and Europe were enrolled and followed for 2 years. LO was graded using the Age-Related Eye Disease Study (AREDS) protocol during slit lamp examinations. Baseline prevalence and 2-year incidence of LO were estimated. Logistic regression with generalized estimating equation was used to identify risk factors associated with LO. RESULTS: Of the 259 participants, 54% were women, 86% were Caucasian, and the median age of STGD1 symptom onset was 19 years. At baseline, median age = 31 (interquartile range [IQR] = 21-44, range = 6-68) years; LO prevalence = 14.3% (69/483) of study eyes. Older age and later disease symptom onset were significantly associated with LO prevalence: for every decade older, adjusted odds ratio (adjOR) = 4.6 (95% confidence interval [CI] = 2.6-7.9); adjOR for every decade later in symptom onset = 0.7 (95% CI = 0.4-1.0). Among the 354 eyes without LO at baseline, 2-year incidence was 5.6%. Older age was associated with incidence: adjOR for every decade older = 4.1 (95% CI = 1.8-9.1). Posterior-subcapsular cataract was rare and nuclear cataract was the most prevalent or incident type. CONCLUSIONS: LO prevalence in ProgStar is higher than in age-matched general population. Age and age of symptom onset were risk factors of LO, suggesting both biological and accelerated aging due to retinal degeneration in STGD1. Trials of STGD1 should closely monitor safety in the anterior segment and consider excluding patients expecting cataract surgery soon.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Ibukun F, Chan BXJ, Khan J, et al. Lens Opacity in ABCA4-Associated Stargardt Disease Patients in the ProgStar Study. Invest Ophthalmol Vis Sci. 2026. PMID: 42484594. doi:10.1167/iovs.67.8.47

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。